AAPP members Bethany DiPaula and David Dadiomov represented psychiatric pharmacy on a panel working from June 2022 through September 2024 to form non-legislative recommendations to improve buprenorphine purchase. The study was recently published in Drug and Alcohol Dependence Reports. The study found that unclear distributor thresholds and fear of regulatory scrutiny are leading pharmacists to ration or avoid dispensing buprenorphine, reducing access to this critical medication. The Pharmacy Access to Resources and Medication for Opioid Use Disorder expert panel developed nine recommendations for the Drug Enforcement Administration, distributors and pharmacists to improve buprenorphine access through nonlegislative changes to current monitoring and distribution practices.